NCT07210307View on ClinicalTrials.gov

Safety Of DAPAGLIFLOZIN (FORXIGA) in Patient With Type 2 Diabetes Mellitus (T2dm) In Vietnam From A Post-Marketing Surveillance Program

CompletedOBSERVATIONAL

Enrollment

1,001

Participants

Timeline

Start Date

October 31, 2017

Primary Completion Date

March 17, 2020

Study Completion Date

March 17, 2020

Conditions

Safety Outcomes

Trial Locations (1)

Unknown

HCMC Heart Institute, Ho Chi Minh City

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY